Compare GSK plc (GSK) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Intuitive Surgical, Inc. — how do they compare? GSK plc trades at $46.66 (market cap $91.88B), while Intuitive Surgical, Inc. trades at $427.05 (market cap $146.76B). The key difference: Intuitive Surgical, Inc. is the larger of the two by market cap, and GSK plc pays a 3.9% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Intuitive Surgical, Inc. for 84 Days on average.
| GSK | ISRG | |
|---|---|---|
Market Cap | $91.88B | $146.76B |
Volume | 7,730,529 | 2,529,814 |
Sector | Health | Health |
52-Week High | $61.18 | $592.85 |
52-Week Low | $43.24 | $332.02 |
Typical Hold Time | 93 Days | 84 Days |
Enterprise Value | $111.88B | $141.54B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Intuitive Surgical (ISRG) trades at $424.58, up 2.43% with strong bullish momentum. The stock shows robust fundamentals with revenue growing from $6.2B in 2022 to $10.1B in 2025 and net profit margins exceeding 28%. Recent earnings consistently beat expectations, with Q2 2026 EPS of $2.80 surpassing the $2.48 forecast. Technical indicators show bullish moving averages with support at $410 and resistance at $419. Analyst consensus remains strongly positive with 70% buy ratings and a $480.78 price target.
ISRG maintains a dominant position in robotic surgery with expanding international growth offsetting China headwinds. The primary investment opportunity lies in continued procedure growth and da Vinci 5 adoption, though risks include competitive pressures and affordability concerns. With strong cash flow generation and institutional support, the stock presents upside potential despite premium valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
